Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes

Effect of Non-steroid Anti-inflammatory Drug on Travoprost-induced Conjunctival Hyperemia and Intraocular Pressure Reduction in Normal Eyes

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02136589

Acronym

ENTICHIR

Enrollment

Registered

2014-05-13

Start date

2008-09-30

Completion date

2008-12-31

Last updated

2014-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperemia, Intraocular Pressure

Brief summary

PG-analogues induce hyperemia as one of side effects in addition to IOP reduction. IOP reduction is caused by direct FP receptor stimulation, but the cause of hyperemia is not clarified. Because FP receptor stimulation induce intrinsic production of PGs, hyperemia or IOP reduction may be due to secondary induced PGs. Thus, pretreatment with NSAID may affect the PG-analogue induced hyperemia or IOP reduction.

Interventions

DRUGdicrofenac and travoprost

dicrofenac drop 3 times a day travoprost 0.005% once daily

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

1. normal healthy eye 2. not applicable for IOP level 3. not wearing contact lenses 4. not applicable for the presence of the ocular surface diseases in case the treatment was not needed

Exclusion criteria

1. the eyes with chronic or recurrent uveitis, scleritis, corneal herpes infection 2. the eyes with the history of trauma, intraocular surgery, or Laser surgery within 6 months 3. the eyes with difficulty for the measurement of IOP with the applanation tonometer 4. the subjects with the allergy for PG-analogues or benzalkonium chloride 5. the subjects using the eyedrops excluding those in this study 6. the subjects treated with oral carbonic anhydrase inhibitor 7. the subject with Sjogren syndrome 8. the subjects who can not drop periodically 9. the subjects with the advanced glaucoma or the terminal stage of glaucoma 10. the subjects with the severe ocular complications

Design outcomes

Primary

Measure	Time frame	Description
IOP reduction	1 day	effect of NSAID on IOP reduction by travoprost

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026